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INTRODUCTION
Chronic urticaria (CU) is a disorder defined as transient and 
itchy wheals for more than 6 weeks and is experienced by 0.1% 
of the general population.1 CU is classified in to chronic sponta-
neous urticaria (CSU) and inducible urticaria by physical stim-
uli.2 Up to 45% of patients with CU have immunoglobulin G 
(IgG) autoantibodies directed against either IgE (5%-10%) or 
FcεRI (35%-40%).3 Patients with CU are at increased risk of hav-
ing autoimmune conditions, and it has been hypothesized that 
the inflammatory processes associated with these autoimmune 
conditions may lead directly to urticaria or increase the individ-
ual’s susceptibility to CU.4
Autoimmune thyroid diseases (AITD), of which Grave’s dis-
ease and Hashimoto’s thyroiditis account for the majority of 
cases, are common autoimmune ones characterized by various 
degrees of lymphocytic infiltration of the thyroid gland and thy-
roid autoantibodies.5 Many previous studies have investigated 
the association between AITD and CSU in a hospital-based de-
sign. However, to our knowledge, only 2 population-based 
studies investigated the association between AITD and CSU, in 
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which they did not use an age- and gender-matched controls.6,7
The aim of this study was to investigate the relative risk of CSU 
in the AITD group compared to the control group using nation-
al registry data of Korea. The primary objective of this study was 
to evaluate the adjusted risk of CSU in patients with AITD. The 
secondary objective was to evaluate other risk factors of CSU, 
including demographic data, and comorbid metabolic and al-
lergic diseases.
MATERIALS AND METHODS
This was a population-based study using the Korean National 
Health Insurance Service National Sample Cohort 2002-2013 
made by the Korean National Health Insurance Service 
(KNHIS). This database was composed of 1,025,340 nationally 
representative random patients and included all medical 
claims from 2002 to 2013.8 KNHIS used the Korean Classifica-
tion of Diseases (KCD), 6th revision, which was similar to the 
International Classification of Diseases (ICD), 10th revision.
The AITD group and the age- and gender-matched control 
group were generated as follows: we excluded patients who 
were treated for AITD or CSU in 2002, and patients under the 
age of 20 years. The AITD group included all patients diagnosed 
as AITD, which included Grave’s disease (KCD/ICD code 
E05.0) and Hashimoto’s thyroiditis (E06.3) between 2003 and 
2005. The control group was composed of randomly selected 
patients who were matched to the AITD group according to age 
and gender at a 1:5 ratio among patients who were not diag-
nosed with AITD in 2002-2013. A specific ICD-10 code for CSU 
is lacking. To overcome this limitation, we used previously vali-
dated algorithm for defining CSU. We defined a diagnosis of 
CSU when one of the following 2 criteria is met for each year 
between 2006 and 2013: (1) either 2 outpatient diagnosis of 
ICD-10 code L50.1 (idiopathic urticaria), L50.8 (other specified 
urticaria), or L50.9 (urticaria, unspecified) at least 6 weeks 
apart; or (2) one outpatient diagnosis of L50.1, L50.8, or L.50.9 
plus one diagnosis of T78.3 (angioneurotic edema) at least 6 
weeks apart. Cherepanov et al.9 investigated validation in this 
algorithm identifying patients with CSU and found that it had a 
positive predictive value of 90.4% and a sensitivity of 71.1%. 
Since original algorithm was made by ICD-9 code, each disease 
code was modified to corresponding ICD-10 code. Demo-
graphic data and comorbidities were collected for each patient. 
The patients were grouped according to household income: 
high-income (20%-100%) and low-income groups (0%-20%). 
They were also grouped according to the region of residence: 
the urban (Seoul, Busan, Daegu, Incheon, Gwangju, Daejeon, 
Ulsan, and Gyeonggi-do) and rural groups (Gangwon-do, 
Chungcheongbuk-do, Chungcheongnam-do, Gyeongsangbuk-
do, Gyeongsangnam-do, Jeollabuk-do, Jeollanam-do, and Jeju-
do). We defined comorbid metabolic diseases, including type 2 
diabetes mellitus (DM), hypertension, and dyslipidemia, in pa-
tients who had both 1or more diagnoses and associated pre-
scribed medication between 2003 and 2005. Comorbid allergic 
diseases, including allergic rhinitis, asthma, and atopic derma-
titis, were defined by 1 or more diagnosis codes between 2003 
and 2005. Chi-square tests were performed to examine the dif-
ferences between the AITD and control groups. To identify the 
hazards associated with CSU, hazard ratios (HRs) and 95% con-
fidence intervals (CIs) were calculated using univariate and 
multivariate Cox proportional hazard regression.
RESULTS
Table 1 shows the demographic data and comorbidities of the 
AITD group (n=3,659) and the control group (n=18,295). In 
the AITD group, the number of patients with Grave’s disease or 
Hashimoto’s thyroiditis was 2,291 (62.6%) or 1,368 (37.4%), re-
spectively. The female gender (80.8%) and age of 40-64 years 
(52.3%) were predominant in the AITD group. The proportion 
of patients with the lower 20% income and rural residence 
group was significantly lower in the AITD group compared with 
the control group (P<0.001). Regarding comorbidities, the pro-
Table 1. Characteristics of the study patients of the AITD (n=3,659) and con-
trol group (n=18,295) 
Variables Control group (n=18,295)
AITD group 
(n=3,659)
P value 
CSU 0.001
   No event 17,585 (96.1) 3,436 (93.9)
   Event 710 (3.9) 223 (6.1)
Age group (year) 1.000
   20-39 6,805 (37.2) 1,361 (37.2)
   40-64 9,570 (52.3) 1,914 (52.3)
   >65 1,920 (10.5) 384 (10.5)
Gender 1.000
   Male 3,520 (19.2) 704 (19.2)
   Female 14,775 (80.8) 2,995 (80.8)
Household income (%) <0.001
   0-20  3,100 (18.3) 443 (12.1)
   21-100  15,195 (83.1) 3,216 (87.9)
Resident area <0.001
   Urban 8,643 (47.2) 1,849 (50.5)
   Rural 9,652 (52.8) 1,810 (49.5)
Comorbidities
   Type 2 DM 939 (5.3) 297 (8.3) <0.001
   Hypertension 2,910 (16.3) 942 (26.4) <0.001
   Dyslipidemia 1,220 (6.8) 478 (13.4) <0.001
   Allergic rhinitis 4,207 (23.0) 1,214 (33.2) <0.001
   Atopic dermatitis 273 (1.5) 117 (3.2) <0.001
   Asthma 1,195 (6.5) 364 (10.0) <0.001
Data are presented as number of patients (%). 
AITD, autoimmune thyroid disease; DM, diabetes mellitus. 
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portions of patients with type 2 DM, hypertension, dyslipid-
emia, allergic rhinitis, atopic dermatitis, or asthma was signifi-
cantly higher in the AITD group compared with the control 
group (P<0.001).
Table 2 shows the HRs for CSU during the 8-year follow-up 
period using univariate and multivariate Cox regression mod-
els. After adjusting for demographic differences and comorbid-
ities, patients with AITD had a significantly higher risk of devel-
oping CSU compared with the control group (adjusted HR, 
1.46; 95% CI, 1.25-1.70; P<0.001). Among the AITD patients, 
the adjusted HR for CSU was higher in patients with Hashimo-
to’s thyroiditis (HR, 1.50; 95% CI, 1.20-1.86; P<0.001) than those 
the patients with Grave’s disease (HR, 1.33; 95% CI, 1.10-1.60; 
P=0.003), although the difference was not statistically signifi-
cant (P=0.368). There was no significantly higher risk of devel-
oping CSU in the age groups of 20-39 (HR, 0.80; 95% CI, 0.63-
1.02) and 40-64 (HR, 1.10; 95% CI, 0.88-1.36), compared to the 
age group of 65+. Female patients had a significantly higher risk 
of CSU compared to male ones (HR, 1.35; P=0.001). Patients 
with type 2 DM (P=0.871), hypertension (P=0.910), or dyslip-
idemia (P=0.696) did not have a significantly higher risk of CSU 
compared to those without. On the other hand, patients with 
allergic rhinitis (HR, 1.51; P<0.001), atopic dermatitis (HR, 2.44; 
P<0.001), or asthma (HR, 1.50; P<0.001) had a significantly 
higher risk of CSU compared to those without.
DISCUSSION
We found that patients with AITD had a greater risk of devel-
oping CSU compared to the control group after adjusting for 
demographic differences and comorbidities. In a study in Isra-
el,6 the diagnosis of CSU was associated with an increased odds 
ratio (OR) for hypothyroidism (OR, 17.338), hyperthyroidism 
(OR, 28.81), and anti-thyroid autoantibodies (P<0.001). How-
ever, the diagnosis was not specifically defined as Grave’s dis-
ease and Hashimoto’s thyroiditis.6 In a study in Italy,7 a history 
of autoimmune thyroiditis did not show a significantly in-
creased risk of CSU. Only 34 CSU patients with a history of au-
toimmune thyroiditis were included.7 Other studies were  hos-
pital-based design with small sample size.10-15 In our study, we 
obtained data from patients with the AITD and controls, and 
these methods were more appropriate for evaluating the asso-
ciation between AITD and CSU. Patients with Hashimoto’s thy-
roiditis had a higher risk of developing CSU than those with 
Grave’s disease, being consistent with the results of previous 
studies.10,11 The exact mechanism linking AITD with CSU re-
mains unknown. Previous reports have demonstrated that anti-
thyroid autoantibodies are significantly increased in CSU pa-
tients compared to healthy patients.12,16 Mozena et al.1 showed 
that neither anti-thyroglobulin nor anti-thyroid peroxidase 
(TPO) autoantibodies are capable of inducing activation of 
mast cells. Previous studies suggested that IgG antithyroid anti-
body rather than IgE antithyroid antibody is prevalent in the 
majority of patients with CSU. However, recent studies17,18 sug-
gested that specific IgE to TPO plays a  role in the pathogenesis 
of CSU. Further studies are required to investigate possible in-
teractions between anti-thyroid antibodies and CSU.
In our study, we found that the proportion of metabolic and 
allergic diseases was significantly higher in the AITD group 
compared to the control group. The association between AITD 
Table 2. Univariate and multivariate Cox regression analysis of CSU development during a 8-year follow-up period
Variables Crude HR (95% Cl) P value Adjusted HR (95% Cl) P value 
Control group Reference Reference Reference Reference
AITD 1.59 (1.37-1.85) <0.001 1.46 (1.25-1.70) <0.001
   Grave’s disease 1.42 (1.18-1.70) <0.001 1.33 (1.10-1.60) 0.003
   Hashimoto’s thyroiditis 1.67 (1.35-2.07) <0.001 1.50 (1.20-1.86) <0.001
Age (year) <0.001 <0.001
   20-39 0.81 (0.65-1.02) 0.80 (0.63-1.02)
   40-64 1.07 (0.87-1.32) 1.10 (0.88-1.36)
   >65 Reference Reference Reference Reference
Gender (female) 1.36 (1.14-1.63) <0.001 1.34 (1.12-1.61) 0.001
Income (lower 20%) 0.84 (0.70-1.01) 0.067 0.87 (0.72-1.04) 0.130
Residence (rural) 1.14 (1.00-1.29) 0.051 1.16 (1.02-1.31) 0.025
Type 2 DM 1.20 (0.84-1.71) 0.325 0.97 (0.66-1.42) 0.871
Hypertension 1.23 (0.98-1.53) 0.075 0.97 (0.77-1.27) 0.910
Dyslipidemia 1.38 (0.98-1.96) 0.067 1.08 (0.74-1.57) 0.696
Allergic rhinitis 1.71 (1.49-1.95) <0.001 1.51 (1.32-1.74) <0.001
Atopic dermatitis 2.84 (2.09-3.86) <0.001 2.44 (1.79-3.32) <0.001
Asthma 1.88 (1.55-2.29) <0.001 1.50 (1.22-1.84) <0.001
CSU, chronic spontaneous urticaria; HR, hazard ratio; CI, confidence interval; AITD, autoimmune thyroid disease; DM, diabetes mellitus.
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and type 1 type 2 DM was reported.19,20 Evolving evidence of in-
teractions between thyroid hormone and basal mechanisms 
controlling appetite and energy expenditure, as well as between 
the regulation of insulin sensitivity and secretion, explains the 
possible association between AITD and metabolic diseases.21 
Previous studies reported a higher incidence of AITD in pa-
tients with allergic disease, and the relationship between aller-
gic and autoimmune diseases was elucidated as 2 potential 
outcomes of dysregulated immunity.22-24
The possible association between metabolic diseases and 
CSU has recently been proposed and investigated.25-27 Ye et al.27 
found a positive relationship between metabolic syndrome and 
CSU in a hospital-based study of 131 patients. In addition, 
Chung et al.26 reported that dyslipidemia is a risk factor for CSU 
in a population-based study. In another population-based 
study, Chang et al.25 showed that CSU is a risk factor for hyper-
tension. However, in our study, there is no significantly in-
creased risk of CSU in patients with type 2 DM, hypertension, 
or dyslipidemia. Previous studies suggested that allergic diseas-
es, such as asthma and allergic rhinitis, could be associated 
with CSU.28,29 In our study, we found that allergic diseases, in-
cluding allergic rhinitis, atopic dermatitis, and asthma, had a 
significantly higher risk of CSU. Further studies are needed to 
elucidate the association between metabolic or allergic diseas-
es and CSU in each disease and matched-control groups.
Our study has some limitations. First, diagnosis of CSU, AITD, 
or other comorbidities was defined on the basis of KCD codes. 
Second by, there could be other confounding factors. Thirdly, 
we did not obtain information on over-the-counter medica-
tions or evaluate drug the adherence. Despite these limitations, 
the strengths of our study are population-based design using a 
nationwide database and generalizability.
In conclusion, after adjusting for demographic differences 
and comorbidities, we demonstrated that patients with AITD 
may have a significantly higher risk of CSU compared to those 
without.
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